• AI
  • Molecular Imaging
  • CT
  • X-Ray
  • Ultrasound
  • MRI
  • Facility Management
  • Mammography

Case Study: PET Imaging with Amyvid for Alzheimer’s

Video

Video: Roberto Soto, MD, of Precision Imaging, shows a recent PET imaging case using Amyvid, recently approved for evaluation of Alzheimer's.

 

 


Roberto Soto, MD, founder and medical officer of Precision Imaging, shows a recent PET imaging case using Amyvid. The radioactive diagnostic agent Amyvid, or florbetapir, was FDA-approved in April for use in the evaluation of Alzheimer’s disease.

In this case, the patient also had an MRI, as seen in the top row. The studies were fused to show additional information. This is a negative Amyvid case, meaning no amyloid plaque was detected and there was a reduced likelihood the impairment is due to Alzheimer’s.
 

Recent Videos
Radiology Study Finds Increasing Rates of Non-Physician Practitioner Image Interpretation in Office Settings
Does Initial CCTA Provide the Best Assessment of Stable Chest Pain?
Nina Kottler, MD, MS
Practical Insights on CT and MRI Neuroimaging and Reporting for Stroke Patients
Related Content
© 2024 MJH Life Sciences

All rights reserved.